Allurion (NYSE: ALUR) surged 83% premarket after revealing a clinical study combining its gastric balloon product with GLP-1 drugs, showing muscle mass maintenance. Stardust Power (NASDAQ ...

Shares of Allurion (NYSE:ALUR) soared 70% in post-market trading Thursday after ending the regular session 21% higher on news the company plans to conduct a clinical study of its gastric balloon ...

550 subjects were randomized 1:1 to either two cycles of the Allurion Balloon 1 or a control group that received moderate intensity lifestyle therapy. Subjects in the treatment group received ...

1 In contrast, in previous studies, patients treated with the Allurion Balloon in combination with the Allurion Virtual Care Suite have demonstrated strong patient outcomes in which patients lose ...

Allurion cited prior studies demonstrating that its gastric balloon, combined with its Virtual Care Suite, has helped patients lose weight while maintaining or even increasing muscle mass.

The Company plans to submit the fourth and final module of the Pre-Market Approval application to the FDA. Topline data were announced from the AUDACITY trial evaluating the Allurion Gastric ...

In Malaysia, cases of overweight and obesity are now increasing at an alarming rate. Photo by Jeslyn Teh. The Allurion intragastric balloon (IGB) is inserted through the mouth into the patient's ...